The DOI matches its Crossref record; the references it cites are not checked yet.
Genetic Analysis of a Multifocal Glioblastoma Multiforme: A Suitable Tool to Gain New Aspects in Glioma Development
Abstract
OBJECTIVE: Multifocal glioblastomas constitute an increasingly diagnosed subgroup of glioblastoma multiforme, the most malignant primary brain tumor in adults. The molecular background of these lesions is unknown. However, the ability to study multiple lesions of one patient simultaneously could provide new aspects in glioma development. METHODS: Short-term cell cultures were derived from three isolated glioblastoma lesions of one patient. Spectral karyotyping and interphase fluorescence in situ hybridization were used for cytogenetic analysis. Loss of heterozygosity was assessed in tumor tissues and cell lines for seven gene loci (p73, p21, p16, PTEN, p27, Rb, p53). In addition, sequence analysis of the PTEN and p53 loci was performed, epidermal growth factor receptor protein expression was assessed, and in vitro proliferation was assayed. RESULTS: A balanced translocation [t(1;15)(p3?6;q2?5)] that has not been described previously in glioblastomas was identified in all cell lines. Primarily, the cell lines have a homozygous deletion of the p16 locus and inactivation of the PTEN gene by loss of heterozygosity and an identical mutation in common. Furthermore, the cell lines harbor a hemizygous (R175H) or two heterozygous (R175H, R213Q) mutations of the p53 gene or none at all. The occurrence of p53 mutations correlates with the size of the original tumors and in vitro proliferation. CONCLUSION: The analysis of a multifocal glioma revealed three main aspects: 1) the combined cytogenetic and molecular analysis of this subgroup of glioblastoma multiforme is a suitable tool to gain new perspectives in glioma development, 2) the balanced translocation [t(1;15)(p3?6;q2?5)] might harbor a new genetic marker involved in glioma development, and 3) the pattern of p53 mutation suggests a role of p53 in the progression of malignancy, migration, and growth of this particular primary glioblastoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mutational status of TP53 is associated with GBM progression [29]”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [29]
Citations
The citation lists haven’t been fetched yet
References 41 · Cited by 42
Metadata
- Authors
- Krex, D., Mohr, B., Appelt, H., Schackert, H. K., & Schackert, G.
- Affiliations
- University Hospital Carl Gustav Carus (DE)
- ORCID
- Schackert, Gabriele
- Venue
- Neurosurgery
- Published
- 2003-12-01
- Volume
- 53
- Issue
- 6
- Pages
- 1377-1384
- ISSN
- 0148-396X (ISSN-L)
- 1524-4040
- OpenAlex
- W2054656134
- Cited by
- 42
- References
- 41
- Citations by year
- 2025: 1 · 2024: 2 · 2022: 4 · 2021: 4 · 2020: 4 · 2018: 1 · 2017: 1 · 2016: 4 · 2015: 1 · 2013: 2 · 2012: 3
- FWCI
- 0.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurosurgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- TP53 mutation, epidermal growth factor receptor, cancer cell lines, tumor progression, in vitro proliferation
- MeSH terms
- Brain Neoplasms, Glioblastoma, Humans, Karyotyping, Male, Middle Aged, Mutation, Phosphoric Monoester Hydrolases, Translocation, Genetic, Genes, p53, Tumor Suppressor Proteins, Cell Line, Tumor, PTEN Phosphohydrolase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review